聯合化療市場規模、佔有率及成長分析（按產品類型、組合類型、應用、最終用戶和地區）－2025-2032 年產業預測

預計 2023 年全球聯合化療市場價值將達到 57.8 億美元，並從 2024 年的 61.5 億美元成長到 2032 年的 101 億美元，預測期內（2025-2032 年）的複合年成長率為 6.4%。

全球聯合化療市場正在經歷強勁成長，主要原因是癌症發生率的上升和藥物組合技術的進步。老年人口日益增多，易患癌症，凸顯了個人化治療方案的必要性。然而，市場面臨的挑戰包括嚴格的法律規範和藥房業務方面的安全問題，凸顯了合規性和病人安全的重要性。另一方面，創新複合技術的開發、精準醫療的普及等新的商業機會也正在湧現，預計將進一步激發市場活力。整體而言，這一前景代表著挑戰和進步的交匯，將決定聯合化療的未來。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局

聯合化療市場規模（按產品類型和複合年成長率） (2025-2032)

• 市場概覽
• 口服
• 注射劑
• 局部的

聯合化療市場規模（按組合類型和複合年成長率） (2025-2032)

• 市場概覽
• 已滅菌
• 非無菌

聯合化療市場規模：按應用和複合年成長率（2025-2032）

• 市場概覽
• 腫瘤學
• 血液學
• 其他

聯合化療市場規模（依最終用戶分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院
• 專科診所
• 居家照護環境
• 其他

聯合化療市場規模：按地區及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• B. Braun Melsungen AG（Germany）
• Fagron NV（Netherlands）
• Baxter International Inc.（USA）
• Fresenius Kabi AG（Germany）
• BioScrip, Inc.（USA）
• Advanced Pharma, Inc.（USA）
• PharMEDium Services, LLC（USA）
• QuVa Pharma, Inc.（USA）
• Nephron Pharmaceuticals Corporation（USA）
• Central Admixture Pharmacy Services, Inc.（USA）
• McGuff Compounding Pharmacy Services, Inc.（USA）
• Cantrell Drug Company（USA）
• Triangle Compounding Pharmacy（USA）
• Wedgewood Pharmacy（USA）
• Pencol Compounding Pharmacy（USA）
• Smiths Medical（USA）
• ICU Medical, Inc.（USA）
• Option Care Health, Inc.（USA）
• Pharmedium Services, LLC（USA）

結論和建議

Global Compounding Chemotherapy Market size was valued at USD 5.78 billion in 2023 and is poised to grow from USD 6.15 billion in 2024 to USD 10.1 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The global compounding chemotherapy market is experiencing robust growth, primarily driven by rising cancer incidence and advancements in pharmaceutical compounding technologies. The growing elderly demographic, which is more prone to cancer, underscores the necessity for personalized treatment solutions. However, the market contends with challenges such as stringent regulatory frameworks and safety concerns related to compounding practices, highlighting the critical importance of compliance and patient safety. On a positive note, emerging opportunities abound, including the development of innovative compounding technologies and the rising adoption of precision medicine, which are set to propel the market further. Overall, the landscape illustrates a blend of challenges and advancements that shape the future of compounding chemotherapy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Compounding Chemotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Compounding Chemotherapy Market Segments Analysis

Global Compounding Chemotherapy Market is segmented by Product Type, Compounding Type, Application, End User and region. Based on Product Type, the market is segmented into Oral, Injectable and Topical. Based on Compounding Type, the market is segmented into Sterile and Non-Sterile. Based on Application, the market is segmented into Oncology, Hematology and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Compounding Chemotherapy Market

The global compounding chemotherapy market is experiencing significant growth driven by the shift towards personalized medicine. As healthcare providers increasingly recognize the importance of individualized treatment plans, there is a heightened demand for customized chemotherapy solutions. Compounding chemotherapy is well-positioned to take advantage of this trend by providing therapies tailored to meet specific patient needs. This includes taking into account unique factors such as genetic profiles, disease characteristics, and individual responses to treatments. By enabling the formulation of bespoke medications, compounding chemotherapy aligns with the evolving healthcare landscape, where personalized approaches are deemed crucial to enhancing treatment efficacy and improving patient outcomes.

Restraints in the Global Compounding Chemotherapy Market

A significant obstacle facing the global compounding chemotherapy market is the lack of standardized practices and formulations. This inconsistency in compounding methodologies raises serious concerns regarding the dependability and effectiveness of compounded chemotherapy medications. Variations in drug formulation, stability, and potency can lead to fluctuations in treatment outcomes for patients, undermining the overall therapeutic effectiveness. Furthermore, the absence of uniform protocols complicates the ability of healthcare providers to assess and compare various compounded formulations, creating additional challenges in ensuring optimal patient care. This variability not only impacts patient safety but also hinders the overall advancement of the compounding chemotherapy sector.

Market Trends of the Global Compounding Chemotherapy Market

The Global Compounding Chemotherapy market is experiencing a transformative trend driven by advances in pharmacogenomics. As healthcare providers increasingly recognize the importance of individualized treatment, the integration of genetic profiling into compounding chemotherapy is becoming paramount. This trend allows for medications to be specifically tailored to a patient's unique genetic makeup, enhancing treatment efficacy and reducing the likelihood of adverse reactions. As a result, the demand for personalized compounding services is rising, propelling market growth. Additionally, increased collaboration among oncologists, pharmacists, and geneticists further supports the expansion of this market, positioning it for significant developments in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Compounding Chemotherapy Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Topical

Global Compounding Chemotherapy Market Size by Compounding Type & CAGR (2025-2032)

• Market Overview
• Sterile
• Non-Sterile

Global Compounding Chemotherapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Hematology
• Others

Global Compounding Chemotherapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Global Compounding Chemotherapy Market Size & CAGR (2025-2032)

• North America (Product Type, Compounding Type, Application, End User)
  • US
  • Canada
• Europe (Product Type, Compounding Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Compounding Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Compounding Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Compounding Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fagron NV (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioScrip, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PharMEDium Services, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuVa Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nephron Pharmaceuticals Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Central Admixture Pharmacy Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• McGuff Compounding Pharmacy Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cantrell Drug Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Triangle Compounding Pharmacy (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wedgewood Pharmacy (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pencol Compounding Pharmacy (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smiths Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICU Medical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Option Care Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmedium Services, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations